Health
Promising Data for Preop Checkpoint Inhibition in NSCLC – MedPage Today
Major response rate of 21%, encouraging survival with single-agent atezolizumab
A fifth of patients with operable early-stage non-small cell lung cancer (NSCLC) had major pathologic responses (MPR) and more than 40% had pathologic downstaging after neoadjuvant atezolizumab (Tecentriq), a prospective multicenter trial showed.
Results showed that 30 of 144 evaluable patients attained MPR, including pathologic complete response (pCR) in 10 patients. Downstaging occurred in 66 of 155 evaluable patients following preoperative treatment with atezolizumab, and 29 patients had upstaging…
-
Noosa News23 hours agoQueensland government to introduced artificial intelligence teaching tool Corella to all state high schools
-
Noosa News22 hours agoMan charged with murder three days after death of 27-year-old in Livingstone, QLD
-
Business14 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News14 hours agoRent changes on way for hundreds of social housing recipients following government review